Adiponectin, though decreased in obesity and promising in preclinical studies as insulin-sensitizing and anti-inflammatory, shows inconsistent links with human cognitive decline, variably associated with both protective and risk profiles across studies. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.